Tuberculosis (TB) is a terrible disease. Although there are first line and second line TB drugs, new medicines are urgently needed given both constantly emerging resistance, as well as the lengthy half-year regimens required for treatment.
An innovative collaboration going by the acronym TBDA (TB Drug Accelerator) will be presented by Abbvie Distinguished Research Fellow Dr. Dale Kempf, Weill Cornell Medicine Associate Professor Ben Gold, moderated by the Gates Foundation Senior Program Officer Dr. Peter Warner. The TBDA brings together 7 major biopharmaceutical companies with leading academic, non-profit and government researchers to “identify new ways to target bacteria that are resistant to current drug regimens, develop new tools for drug discovery, and discover new drugs that can lead to accelerated treatments.”
The scientific challenges are significant given the 28-day replication cycle, BSL assays, and the inherent resilience and complexity of TB biology. Come learn more from the leading edge as scientists roll up their sleeves to work together on this centuries old challenge.
Join our distinguished panel of speakers as they deviate from the expected “PowerPoint presentation” style webinar to provide an engaging Town Hall experience.
Big thanks to our sponsors for allowing us to freely share these timely updates:
Also thanks to the Research Data Alliance.
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities.
CDD Vault: Drug Discovery Informatics your whole project team will embrace
Translated with Google Translate